Reports Q4 revenue $22.5B, consensus $22.45B. “2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and CEO, Johnson & Johnson. “As a healthcare company, with a disease-centric approach, we are improving the standard of care in a broad range of diseases with high unmet need, including multiple myeloma, lung cancer, inflammatory bowel disease, and heart failure. With our strong financial foundation, differentiated portfolio and robust pipeline, we are well positioned to sustain the high pace of growth and innovation that is the hallmark of Johnson & Johnson.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Reviva Pharmaceuticals price target lowered to $11 from $14 at H.C. Wainwright
- Johnson & Johnson’s Nasal Spray Gets FDA Nod for Depression Treatment
- Intra-Cellular downgraded to Sector Perform from Outperform at RBC Capital
- Notable companies reporting before tomorrow’s open
- Johnson & Johnson announces FDA approves sNDA for Spravato